Can Amylyx Pharmaceuticals, Inc. cover its short-term obligations?

Its current ratio is 17.85 — current assets exceed current liabilities.

Where does Amylyx Pharmaceuticals, Inc.'s balance sheet data come from?

Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Amylyx Pharmaceuticals, Inc. AMLX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$226.65M+193%	$77.39M-54.5%	$170.2M+172%	$62.53M+24.6%
Short-term investments	$90.33M-8.9%	$99.11M-50.7%	$201.16M-29.3%	$284.42M+519%
Prepaid expenses and other current assets	$33.69M-34.4%	$51.33M-9.6%	$56.81M+48.7%	$38.19M+434%
Total current assets	$323.67M+70.9%	$189.43M-59.2%	$464.67M+21.6%	$382.13M+264%
Property and equipment, net	$310K-67.7%	$961K-64.2%	$2.69M+2.9%	$2.61M+451%
Operating lease right-of-use assets	$5.18M+193%	$1.77M-52.5%	$3.73M-32.6%	$5.52M—
Other non-current assets	$2.5M+10,308%	$24K-96.6%	$701K+50.4%	$466K—
Total assets	$332.65M+71.8%	$193.63M-62.6%	$517.45M+32.2%	$391.45M+271%
Accounts payable	$16.96M-45.0%	$30.83M-51.7%	$63.9M+103%	$31.47M+761%
Accrued expenses	$17.91M-25.2%	$23.95M-58.5%	$57.72M+50.7%	$38.31M+194%
Operating lease liabilities, current	$1.26M-17.1%	$1.52M-32.7%	$2.26M+10.6%	$2.04M—
Total current liabilities	$22.69M-20.1%	$28.41M-65.4%	$82.04M+76.0%	$46.61M+168%
Operating lease liabilities, non-current	$4.7M+915%	$463K-76.6%	$1.98M-53.3%	$4.24M—
Total liabilities	$27.39M-5.1%	$28.87M-65.6%	$84.02M+65.2%	$50.85M+192%
Common stock	$11K+57.1%	$7K0.0%	$7K0.0%	$7K+600%
Additional paid-in capital	$1.06B+36.9%	$771.54M+4.5%	$738.18M+6.2%	$694.91M+14,790%
Retained earnings	-$751.43M-23.9%	-$606.69M-98.9%	-$304.95M+13.9%	-$354.22M-127%
Accumulated other comprehensive income (loss)	$404K+539%	-$92K-147%	$197K+329%	-$86K-1,056%
Total stockholders' equity	$305.26M+85.3%	$164.77M-62.0%	$433.43M+27.3%	$340.61M+325%
Total liabilities and stockholders' equity	$332.65M+71.8%	$193.63M-62.6%	$517.45M+32.2%	$391.45M+271%
Short- term Investments	$90.33M-8.9%	$99.11M-50.7%	$201.16M—	——
Deferred Tax Assets and Other Non-Current Assets	$2.5M+10,308%	$24K-96.6%	$701K+50.4%	$466K—
Net Investment in Lease	$5.18M+193%	$1.77M-52.5%	$3.73M-32.6%	$5.52M—
Deposits And Other Assets	$2.5M+10,308%	$24K—	——	——
Operating lease right-of-use assets	$5.18M+193%	$1.77M-52.5%	$3.73M-32.6%	$5.52M—
Other non-current assets	$2.5M+10,308%	$24K-96.6%	$701K+50.4%	$466K—
Operating Lease Right-of-Use Assets in Other Assets	$5.18M+193%	$1.77M-52.5%	$3.73M-32.6%	$5.52M—
Software and Technology Licenses, Net	$2.5M+10,308%	$24K-96.6%	$701K+50.4%	$466K—
Other Commercial Liabilities	$17.91M-25.2%	$23.95M-58.5%	$57.72M+50.7%	$38.31M—
Accrued Liabilities, Current	$17.91M-25.2%	$23.95M-58.5%	$57.72M+50.7%	$38.31M—
Total debt	$5.96M+201%	$1.98M-53.2%	$4.24M-32.5%	$6.28M—
Additional paid-in capital	$1.06B+36.9%	$771.54M+4.5%	$738.18M+6.2%	$694.91M+14,790%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$11K+57.1%	$7K0.0%	$7K0.0%	$7K+600%
Restricted cash equivalents included in Other long-term assets	$985K-31.9%	$1.45M+101%	$719K0.0%	$719K+280%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Amylyx Pharmaceuticals, Inc. cover its short-term obligations?: Its current ratio is 17.85 — current assets exceed current liabilities.
Where does Amylyx Pharmaceuticals, Inc.'s balance sheet data come from?: Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.